相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pharmacogenomics of warfarin: Uncovering a piece of the warfarin mystery
Michael P. Gulseth et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2009)
Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review
Glenn E. Palomaki et al.
GENETICS IN MEDICINE (2009)
Clopidogrel in acute coronary syndrome: to genotype or not?
Robert F. Storey
LANCET (2009)
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study
Jean-Philippe Collet et al.
LANCET (2009)
Brain Drug-Metabolizing Cytochrome P450 Enzymes are Active In Vivo, Demonstrated by Mechanism-Based Enzyme Inhibition
Sharon Miksys et al.
NEUROPSYCHOPHARMACOLOGY (2009)
Cytochrome P-450 Polymorphisms and Response to Clopidogrel.
Jessica L. Mega et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Genetic Determinants of Response to Clopidogrel and Cardiovascular Events.
Tabassome Simon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Drug-diagnostic codevelopment strategies: FDA and industry dialog at the 4th FDA/DIA/PhRMA/PWG/BIO Pharmacogenomics Workshop
Lois Hinma et al.
PHARMACOGENOMICS (2009)
Designing pharmacogenetic projects in industry: practical design perspectives from the Industry Pharmacogenomics Working Group
C. M. Bromley et al.
PHARMACOGENOMICS JOURNAL (2009)
Effect of cytochrome P450 polymorphisms on platelet reactivity after treatment with Clopidogrel in acute coronary syndrome
Corinne Frere et al.
AMERICAN JOURNAL OF CARDIOLOGY (2008)
The Use of Genomics in Clinical Trial Design
Richard Simon
CLINICAL CANCER RESEARCH (2008)
The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: A possible mechanism for clopidogrel resistance
K. A. Kim et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: Comparison with Korean, Chinese, and Caucasian populations
S. P. Myrand et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
A Rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding
Monica R. McClain et al.
GENETICS IN MEDICINE (2008)
Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study
Iris Grossman et al.
GENETICS IN MEDICINE (2008)
PhRMA white paper on ADME pharmacogenomics
J. Andrew Williams et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents
Dietmar Trenk et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Defining drug disposition determinants: a pharmacogenetic-pharmacokinetic strategy
David A. Katz et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Genome-wide association studies for complex traits: consensus, uncertainty and challenges
Mark I. McCarthy et al.
NATURE REVIEWS GENETICS (2008)
Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression
Manfred Uhr et al.
NEURON (2008)
CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation
Tobias Geisler et al.
PHARMACOGENOMICS (2008)
Global analysis of genetic variation in SLCOIB1
Marja K. Pasanen et al.
PHARMACOGENOMICS (2008)
Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19*2 allele on clopidogrel responsiveness
Pierre Fontana et al.
THROMBOSIS RESEARCH (2008)
Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition
S. -F. Zhou
XENOBIOTICA (2008)
The CYP2D6 activity score: Translating genotype information into a qualitative measure of phenotype
A. Gaedigk et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel
J. T. Brandt et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Genetic markers of suicidal ideation emerging during citalopram treatment of major depression
Gonzalo Laje et al.
AMERICAN JOURNAL OF PSYCHIATRY (2007)
Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17
Hongwu Shen et al.
DRUG METABOLISM AND DISPOSITION (2007)
Increased risk for major depression associated with the short allele of the serotonin transporter promoter region (5-HTTLPR-S) and the CYP2C9*3 allele
P. Dorado et al.
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2007)
The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite
A. Sugidachi et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Cytochrorne P4502C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects
Jean-Sebastien Hulot et al.
BLOOD (2006)
Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel
Dominick J. Angiolillo et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450
JLF Rehmel et al.
DRUG METABOLISM AND DISPOSITION (2006)
Biology and pharmacology of the platelet P2Y(12) receptor
Robert F. Storey
CURRENT PHARMACEUTICAL DESIGN (2006)
The effect of cigarette smoking on the hypnotic efficacy of propofol
C. Lysakowski et al.
ANAESTHESIA (2006)
Clinical correlates of tardive dyskinesia in schizophrenia: Baseline data from the CATIE schizophrenia trial
DD Miller et al.
SCHIZOPHRENIA RESEARCH (2005)
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia
JA Lieberman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia:: a meta-analysis
NA Patsopoulos et al.
PHARMACOGENETICS AND GENOMICS (2005)
Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity
M Ingelman-Sundberg
PHARMACOGENOMICS JOURNAL (2005)
Clinical consequences of cytochrome P4502C9 polymorphisms
J Kirchheiner et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P4502B6 in human liver microsomes
LM Hesse et al.
PHARMACOGENETICS (2004)
Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus
DA Hesselink et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
Classification analysis of P-glycoprotein substrate specificity
R Didziapetris et al.
JOURNAL OF DRUG TARGETING (2003)
Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis
S MacGillivray et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: Schizophrenia trial design and protocol development
TS Stroup et al.
SCHIZOPHRENIA BULLETIN (2003)
Structure and stereochemistry of the active metabolite of clopidogrel
JM Pereillo et al.
DRUG METABOLISM AND DISPOSITION (2002)
ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-Segment elevation myocardial infarction - Summary article - A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina)
E Braunwald et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2002)
Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and Tardive dyskinesia in schizophrenia
TG Schulze et al.
AMERICAN JOURNAL OF MEDICAL GENETICS (2001)
CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite norclozapine steady-state concentration in patients with schizophrenia
V Özdemir et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2001)
The effect of smoking on postoperative nausea and vomiting
W Chimbira et al.
ANAESTHESIA (2000)
分享论文
